The economy and the markets are "under surveillance" as we cover the latest in finance, economics and investment. Listen to Jonathan Ferro, Lisa Abramowicz and Annmarie Hordern for the top interviews from Bloomberg Surveillance Television. And join Tom Keene and Paul Sweeney for the best conversations from Bloomberg Surveillance Radio. Watch Surveillance TV LIVE each mornings: http://bit.ly/3P7nstQ. Watch Surveillance Radio LIVE weekday mornings: http://bit.ly/3vTiACF.
…
continue reading
Content provided by Radio America. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Radio America or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Trump vs. Big Pharma: Art of the Deal or Just Another Executive Order?
MP3•Episode home
Manage episode 482316778 series 1081845
Content provided by Radio America. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Radio America or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Listen on:
Apple Podcasts:https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608
Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i
Watch on: https://www.youtube.com/@WatchdogOnWallstreet/featured
Chris breaks down Trump’s executive order aimed at lowering U.S. prescription drug prices—and why it likely won’t survive a legal challenge. He explains how Americans bear the brunt of global R&D costs due to foreign price controls and argues that real reform lies in negotiation, not government-mandated price fixing. Markowski draws from his experience in pharmaceutical investment banking to expose the high stakes of drug development and offers potential “Art of the Deal” tactics Trump could use—like restricting pharma ad spending—to push foreign governments to pay their fair share. He warns that true price controls would kill innovation and devastate the industry. www.watchdogonwallstreet.com
…
continue reading
Apple Podcasts:https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608
Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i
Watch on: https://www.youtube.com/@WatchdogOnWallstreet/featured
Chris breaks down Trump’s executive order aimed at lowering U.S. prescription drug prices—and why it likely won’t survive a legal challenge. He explains how Americans bear the brunt of global R&D costs due to foreign price controls and argues that real reform lies in negotiation, not government-mandated price fixing. Markowski draws from his experience in pharmaceutical investment banking to expose the high stakes of drug development and offers potential “Art of the Deal” tactics Trump could use—like restricting pharma ad spending—to push foreign governments to pay their fair share. He warns that true price controls would kill innovation and devastate the industry. www.watchdogonwallstreet.com
1700 episodes
MP3•Episode home
Manage episode 482316778 series 1081845
Content provided by Radio America. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Radio America or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Listen on:
Apple Podcasts:https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608
Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i
Watch on: https://www.youtube.com/@WatchdogOnWallstreet/featured
Chris breaks down Trump’s executive order aimed at lowering U.S. prescription drug prices—and why it likely won’t survive a legal challenge. He explains how Americans bear the brunt of global R&D costs due to foreign price controls and argues that real reform lies in negotiation, not government-mandated price fixing. Markowski draws from his experience in pharmaceutical investment banking to expose the high stakes of drug development and offers potential “Art of the Deal” tactics Trump could use—like restricting pharma ad spending—to push foreign governments to pay their fair share. He warns that true price controls would kill innovation and devastate the industry. www.watchdogonwallstreet.com
…
continue reading
Apple Podcasts:https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608
Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i
Watch on: https://www.youtube.com/@WatchdogOnWallstreet/featured
Chris breaks down Trump’s executive order aimed at lowering U.S. prescription drug prices—and why it likely won’t survive a legal challenge. He explains how Americans bear the brunt of global R&D costs due to foreign price controls and argues that real reform lies in negotiation, not government-mandated price fixing. Markowski draws from his experience in pharmaceutical investment banking to expose the high stakes of drug development and offers potential “Art of the Deal” tactics Trump could use—like restricting pharma ad spending—to push foreign governments to pay their fair share. He warns that true price controls would kill innovation and devastate the industry. www.watchdogonwallstreet.com
1700 episodes
Усі епізоди
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.